Ovarian Cancer: Risk-Reducing Surgery for High-Risk Individuals

Risk-reducing surgery, primarily Risk-Reducing Salpingo-Oophorectomy (RRSO), plays a pivotal role in mitigating the risk of ovarian cancer, especially for individuals with genetic predispositions such as BRCA1 and BRCA2 gene mutations. This surgical intervention involves the removal of healthy ovaries and fallopian tubes to prevent cancer development. Decades of research affirm its effectiveness, demonstrating a substantial reduction in the risk of ovarian and fallopian tube cancer, estimated at 80-90%. Furthermore, RRSO may also reduce the risk of breast cancer in certain high-risk women and can improve overall mortality. The rationale behind RRSO is strongly supported by the high lifetime risk of ovarian cancer associated with germline BRCA1/2 mutations. These mutations are found in 10-15% of women diagnosed with ovarian cancer. For BRCA1 mutation carriers, the cumulative lifetime risk of developing high-grade serous carcinoma (HGSC) can approach 40%, while for BRCA2 carriers, it is around 20% by the age of 70-80 years. Given the lack of effective early screening methods for ovarian cancer, which often leads to late-stage diagnosis and a five-year survival rate of less than 50%, preventive strategies like RRSO are critical. The timing of RRSO is a crucial aspect of patient counseling and decision-making. Guidelines generally recommend RRSO for BRCA1 mutation carriers between the ages of 35 and 40 years, or upon completion of childbearing. For BRCA2 mutation carriers, delaying the surgery until age 40-45 years may be considered, as the onset of ovarian cancer risk tends to be later in this group. Patient priorities, including childbearing plans and concerns about potential menopausal symptoms, significantly influence these decisions. It is essential to balance the substantial cancer-reducing benefits of RRSO with the increased morbidity that can arise from premature menopause, which includes symptoms like hot flashes, mood changes, and long-term health implications such as bone density loss and cardiovascular effects. Hormone replacement therapy (HRT) may be considered to manage menopausal symptoms post-surgery, with careful consideration of individual risks and benefits. While RRSO offers significant protection, it does not completely eliminate the risk of cancer. A small residual risk of primary peritoneal cancer (approximately 3-4%) remains, particularly in BRCA1 mutation carriers, as peritoneal tissue can also develop similar cancers. Research is also exploring alternative approaches like salpingectomy, which involves removing only the fallopian tubes. This option is being studied for high-risk women who are not yet ready to undergo oophorectomy (removal of ovaries), allowing them to potentially delay menopause. However, the long-term effectiveness of salpingectomy alone in significantly reducing ovarian cancer risk in high-risk individuals is still under investigation, and a subsequent oophorectomy is often recommended once childbearing is complete. The relevance of this topic extends globally, with particular significance for countries like India. Ovarian cancer is the third most common cancer among women in India, claiming more lives than breast and cervical cancers. Studies indicate that the prevalence of BRCA positivity in Indian breast cancer patients can range from 9% to 25%. Despite the clear benefits of genetic testing and risk-reduction strategies, their adoption in India faces several challenges. These include a scarcity of data on BRCA mutation prevalence, limited awareness among physicians, and issues related to the availability and prohibitive cost of genetic testing and counseling. Expert consensus documents, such as those from the Indian Society of Medical and Pediatric Oncology, are crucial in providing practical insights and recommendations for identifying patients suitable for genetic counseling and testing, and for guiding management strategies for hereditary breast and ovarian cancer (HBOC) syndrome in the Indian context. Efforts are needed to increase accessibility to genetic testing and counseling services, and to raise awareness among both healthcare providers and the public about the importance of early detection and preventive measures for high-risk individuals. In conclusion, risk-reducing surgery is a highly effective, evidence-based intervention for individuals at high genetic risk of ovarian cancer. While requiring careful consideration of patient-specific factors, particularly the impact of premature menopause, its role in preventing a highly aggressive cancer is undeniable. Continued efforts in genetic counseling, widespread testing, and public awareness are crucial for optimizing its utilization globally, including in India, to improve outcomes for women at risk.

Frequently Asked Questions

Read Full Story on Quick Digest